

BAM7

Catalog No: **tcsc1453**



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

331244-89-4

Formula:

$C_{21}H_{19}N_5O_2S$

Pathway:

Apoptosis

Target:

Bcl-2 Family

Purity / Grade:

>98%

Solubility:

DMSO : 5 mg/mL (12.33 mM; Need ultrasonic)

Observed Molecular Weight:

405.47


Product Description

BAM7 is a direct and selective activator of proapoptotic **BAX** with an **IC₅₀** of 3.3 μM.

IC50 & Target: IC50: 3.3 μM (BAX)^[1]

In Vitro: BAM7 is selective for the BH3-binding site on BAX. BAM7 activates BAX and BAX-dependent cell death. Whereas treatment with BAX or BAM7 alone has no effect on the liposomes, the combination of BAM7 and BAX yields dose-responsive liposomal release

of entrapped fluorophore. BAM7 dose- and time-responsively impairs the viability of *Bak*^{-/-} MEFs that exclusively express BAX but has no effect on *Bak*^{-/-} MEFs that contain BAK but lack BAX. In contrast, standard proapoptotic stimuli such as serum withdrawal, Staurosporine and Etoposide induces an equivalent apoptotic response in *Bax*^{-/-} and *Bak*^{-/-} MEFs. As further evidence of BAM7 specificity of action, (i) BAM7 does not affect the viability of *Bax*^{-/-} *Bak*^{-/-} MEFs; (ii) ANA-BAM16, which does not bind or activate BAX, has no effect on *Bak*^{-/-} MEFs; and (iii) BAM7 selectively induces cell death of *Bax*^{-/-} *Bak*^{-/-} MEFs reconstituted with wild-type BAX but not BAXK21E, which bears the mutation that abrogates BAM7 binding^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!